Abstract Number: 0541 • ACR Convergence 2023
Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…Abstract Number: 2280 • ACR Convergence 2023
The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Background/Purpose: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinican-reported outcome (ClinRO) correlates well with other disease activity indices such us…Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…Abstract Number: 0157 • ACR Convergence 2023
Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective
Background/Purpose: During times of social-distancing, in-person outpatient visits were greatly reduced. Health care professionals (HCPs) were dependent on the patient's reported experience of their disease…Abstract Number: 0398 • ACR Convergence 2023
Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is the result of the complex interplay between genetic, epigenetic, and environmental factors leading to immune dysregulation, synovial membrane inflammation, and…Abstract Number: 0554 • ACR Convergence 2023
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by varied disease activity, underscored by complex immune dysregulation, including altered immune mediators and…Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…Abstract Number: 1400 • ACR Convergence 2023
Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Background/Purpose: ASDAS-CRP is a composite score that measures disease activity in axial spondyloarthritis (axSpA) and is based on patient-reported outcomes and objective measures of inflammation.…Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 91
- Next Page »